BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 22571611)

  • 1. The emerging role of CXC chemokines and their receptors in cancer.
    Vinader V; Afarinkia K
    Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression and role of CXC chemokines in colorectal cancer.
    Verbeke H; Struyf S; Laureys G; Van Damme J
    Cytokine Growth Factor Rev; 2011; 22(5-6):345-58. PubMed ID: 22000992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CXC chemokines and their receptors in cancer.
    Vandercappellen J; Van Damme J; Struyf S
    Cancer Lett; 2008 Aug; 267(2):226-44. PubMed ID: 18579287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
    Xia Y; Choi HK; Lee K
    Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
    Verma SK; Knight SD
    Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
    Cabrero-de Las Heras S; Martínez-Balibrea E
    World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock proteins in cancer: targeting the 'chaperones'.
    Nahleh Z; Tfayli A; Najm A; El Sayed A; Nahle Z
    Future Med Chem; 2012 May; 4(7):927-35. PubMed ID: 22571616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
    Kim DH; Sim T
    Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cells as a target population for drug discovery.
    Bouvard C; Barefield C; Zhu S
    Future Med Chem; 2014 Sep; 6(14):1567-85. PubMed ID: 25367391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution and functional characterization of CXC chemokines and receptors in lamprey.
    Sun Z; Qin Y; Liu D; Wang B; Jia Z; Wang J; Gao Q; Zou J; Pang Y
    Dev Comp Immunol; 2021 Mar; 116():103905. PubMed ID: 33164777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Eph/ephrin system in cancer therapy.
    Lodola A; Giorgio C; Incerti M; Zanotti I; Tognolini M
    Eur J Med Chem; 2017 Dec; 142():152-162. PubMed ID: 28780190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylamine N-acetyltransferase 1: a novel drug target in cancer development.
    Butcher NJ; Minchin RF
    Pharmacol Rev; 2012 Jan; 64(1):147-65. PubMed ID: 22090474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
    Seo SY
    Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activators of PKM2 in cancer metabolism.
    Warner SL; Carpenter KJ; Bearss DJ
    Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
    Maira SM; Furet P; Stauffer F
    Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.
    Engl T; Relja B; Blumenberg C; Müller I; Ringel EM; Beecken WD; Jonas D; Blaheta RA
    Life Sci; 2006 Mar; 78(16):1784-93. PubMed ID: 16263140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [G-quadruplex ligands: mechanisms of anticancer action and target binding].
    Il'inskiĭ NS; Varizhuk AM; Beniaminov AD; Puzanov MA; Shchelkina AK; Kaliuzhnyĭ DN
    Mol Biol (Mosk); 2014; 48(6):891-907. PubMed ID: 25845230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule regulators of autophagy and their potential therapeutic applications.
    Zhou M; Wang R
    ChemMedChem; 2013 May; 8(5):694-707. PubMed ID: 23568434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.